SecBot SecBot
SECBOTREPLAY Home › Report › VIR

VIR · Shelf registration for debt

Vir Biotechnology, Inc. · S-3ASR filed Nov 12, 2026 at 16:02 ET

At the news

NEUTRALIMPACT 3/10

S-3ASR filed Nov 12, 2026 at 16:02 ET

Vir Biotechnology filed an automatic shelf registration (S-3ASR) to register an unlimited amount of senior and subordinated debt securities for future issuance. The filing does not specify any immediate offering size, pricing, or use of proceeds. The company has $901.3M in cash and investments as of September 30, 2026, and recently entered a Gilead collaboration worth up to $1.74B in milestones, suggesting this shelf is opportunistic rather than a distress-driven capital raise. The filing follows a recent activist stake reduction by ARCH Venture Fund and a Q3 2026 earnings report showing a narrowed net loss.

  • S-3ASR filed registering an unlimited amount of senior and subordinated debt securities
  • No specific offering size, pricing, or use of proceeds stated in the filing
  • Company had $901.3M in cash and investments as of September 30, 2026
  • Q3 2026 net loss of $96.3M ($0.57 per share), narrowed from $163.1M in Q3 2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access